Lexicon Has A Lot Riding On LX9211 Phase IIb Readout In Pain

CEO Mike Exton talked to Scrip about moving the company forward after a disappointingly disruptive 2024.

(Shutterstock)
Key Takeaways
  • Lexicon is squarely focused on a Phase IIb data readout for pilavapadin, or LX9211, for diabetic peripheral neuropathic pain (DPNP), coming in the first quarter.

Lexicon Pharmaceuticals has an important data readout coming in the first quarter for a Phase IIb study testing pilavapadin, or...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Interviews

Degron Eyes Deals For Novel Molecular Glue Degrader Assets

 

Pursuing first-in-class molecular glue degraders using undruggable targets could eventually help Degron Therapeutics land sizable asset-based deals, CEO Lily Zou tells Scrip.

MetaVia Sees Obesity Opportunities Despite Challenging US Market

 
• By 

Despite new challenges related to obesity drug insurance coverage in the US, MetaVia's CEO is confident in the company's novel contender, which unlike rival GLP-1 therapies doesn’t require dose titration.

Quotables: Pharma Leaders On The Month’s Hot Topics

 

The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.

Roivant Staying ‘Patient’ On Deals, Leaving Investors Waiting

 

CEO Matt Gline talked to Scrip in an interview about dealmaking and the road back to commercialization.

More from Conferences

Merus Raises $300m After ASCO Success

 

The company is raising the money to fuel development of its head and neck cancer candidate, petosemtamab, on the back of promising early data. Some analysts are stopping short of declaring it the winner against a rival product from Bicara, however.

Bayer Boosted By Third FDA Approval For Nubeqa

 
• By 

US green light will further expand sales of the prostate cancer blockbuster.

ASCO: Zepzelca Tecentriq Combo A Lung Cancer Success For Jazz and Roche

 

Small-cell lung cancer treatment is rapidly evolving, but Jazz and Roche are set to create a new maintenance therapy setting with their Zepzelca plus Tecentriq combination.